Thyrotropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Thyrotropin alfa: From Thyroid Diagnostic/Adjunctive Use to Migraine Disorder
One-Sentence Summary
Thyrotropin alfa is a recombinant human thyroid-stimulating hormone (TSH), marketed in Singapore as Thyrogen, and used in thyroid-related diagnostic and adjunctive settings. The TxGNN model predicts it may be effective for migraine disorder, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, thyrotropin alfa is a recombinant TSH that acts on the TSH receptor on thyroid follicular cells. Its established use is in thyroid cancer management, as a diagnostic and adjunctive agent, rather than in neurological disease.
No biological pathway connecting TSH receptor agonism to migraine is supported by the available data. The high score (0.9998, rank 514) most likely reflects proximity within the knowledge graph rather than a drug-specific mechanism. Related migraine-cluster predictions (migraine with brainstem aura, migraine susceptibility) appear to come from the same graph neighbourhood and add no independent support.
Other top-ranked predictions are similarly unsupported. Raynaud disease, pulmonary hypertension and postural orthostatic tachycardia syndrome have only indirect links through thyroid status. For hyperthyroidism, the direction is mechanistically contradictory, since stimulating the TSH receptor would increase thyroid hormone output. That prediction is better treated as a safety flag than a repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13164P | Thyrogen 0.9 mg Powder for Solution for Injection | Injection, powder, for solution | Not stated in the licence record |
Safety Considerations
Drug Interactions: 45 potential interactions were identified, all classified as Moderate. The main ones involve glucose-lowering agents, including:
- Sulfonylureas (glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide)
- Metformin and acarbose
- DPP-4 inhibitors (alogliptin, saxagliptin)
- GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, semaglutide)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
- Insulins (human insulin, insulin aspart)
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction is supported only by a knowledge-graph score. There are no clinical trials, no publications, and no plausible mechanistic link between TSH receptor agonism and migraine pathophysiology. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data (e.g. from DrugBank) and a credible biological rationale linking TSH receptor signalling to migraine
- Package insert warnings and contraindications from HSA, which are required for safety screening
- Preclinical or observational evidence supporting any neurological effect
- Confirmation of the approved indication text for SIN13164P
- A route and dosing feasibility assessment for a chronic neurological indication, since the product is an injectable used in intermittent diagnostic and adjunctive settings
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.